Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J. Clin.60,277–300 (2010).
  MedlineGoogle Scholar
• 2  Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet363,1049–1057 (2004).
  Medline CASGoogle Scholar
• 3  Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15,2403–2413 (1997).
  Medline CASGoogle Scholar
• 4  Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol.7,163–172 (2010).
  Medline CASGoogle Scholar
• 5  Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25,1960–1966 (2007).
  Medline CASGoogle Scholar
• 6  Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med.364,1817–1825 (2011).▪▪ First study to demonstrate that the combination of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is a first-line option for patients with metastatic pancreatic cancer who are younger than 76 years of age and who have a good performance status (i.e., Eastern Cooperative Oncology Group 0 or 1), no cardiac ischemia and normal or nearly normal bilirubin levels.
  Medline CASGoogle Scholar
• 7  Reni M, Cordio S, Milandri C et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre Phase III trial. Lancet Oncol.6,369–376 (2005).▪▪ First study to demonstrate the activity of cisplatin/epirubicin/fluorouracil/gemcitabine regimen in advanced pancreatic cancer.
  Medline CASGoogle Scholar
• 8  Reni M, Bonetto E, Cordio S et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a Phase III randomized trial. Pancreatology6,454–463 (2006).
  Medline CASGoogle Scholar
• 9  Reni M, Cereda S, Rognone A et al. A randomized Phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother. Pharmacol. doi:10.1007/s00280-011-1680-2 (2011) (Epub ahead of print).
  MedlineGoogle Scholar
• 10  Mambrini A, Pacetti P, Del Freo A et al. Gemcitabine–capecitabine plus intra-arterial epirubicin–cisplatin in pretreated pancreatic cancer patients: a Phase I study. Anticancer Res.29,1547–1549 (2009).
  Medline CASGoogle Scholar
• 11  Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res.66,3928–3935 (2006).
  Medline CASGoogle Scholar
• 12  Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer120,1355–1363 (2007).
  Medline CASGoogle Scholar
• 13  Nakano Y, Tanno S, Koizumi K et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer96,457–463 (2007).▪ Comprehensive review on molecular markers associated with gemcitabine transport and metabolism.
  Medline CASGoogle Scholar
• 14  Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther.5,1387–1395 (2006).
  Medline CASGoogle Scholar
• 15  Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin. Cancer Res.14,1284–1285 (2008).
  Medline CASGoogle Scholar
• 16  Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med.355,983–991 (2006).
  Medline CASGoogle Scholar
• 17  Danesi R, Pasqualetti G, Giovannetti E et al. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv. Drug Deliv. Rev.61,408–417 (2009).
  Medline CASGoogle Scholar
• 18  Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer116,5325–5335 (2010).
  Medline CASGoogle Scholar
• 19  Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res.16,320–329 (2010).
  Medline CASGoogle Scholar
• 20  Dong X, Jiao L, Li Y et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J. Clin. Oncol.27,1592–1599 (2009).
  Medline CASGoogle Scholar
• 21  Chen J, Li D, Killary AM et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann. Surg. Oncol.16,431–439 (2009).
  MedlineGoogle Scholar
• 22  Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin. Cancer Res.14,2042–2048 (2008).
  Medline CASGoogle Scholar
• 23  Li D, Liu H, Jiao L et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res.66,3323–3330 (2006).
  Medline CASGoogle Scholar
• 24  Li D, Frazier M, Evans DB et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J. Clin. Oncol.24,1720–1728 (2006).
  Medline CASGoogle Scholar
• 25  Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer44,311–316 (2004).
  MedlineGoogle Scholar
• 26  Gurubhagavatula S, Liu G, Park S et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol.22,2594–2601 (2004).▪▪ Important study to demonstrate the role of DNA repair gene polymorphisms in the anticancer effect of platinum chemotherapy.
  Medline CASGoogle Scholar
• 27  Wei SZ, Zhan P, Shi MQ et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol.28,315–321 (2011).
  Medline CASGoogle Scholar
• 28  Giovannetti E, Funel N, Peters GJ et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res.70,4528–4538 (2010).
  Medline CASGoogle Scholar
• 29  Giovannetti E, Zucali PA, Peters GJ et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol. Cancer Ther.9,581–593 (2010).
  Medline CASGoogle Scholar
• 30  Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl Cancer Inst.96,434–442 (2004).
  MedlineGoogle Scholar
• 31  Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol.24,3946–3952 (2006).
  Medline CASGoogle Scholar
• 32  Colucci G Labianca R, Di Costanzo F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol.28,1645–1651 (2010).
  Medline CASGoogle Scholar
• 33  Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol. Ther.87,227–253 (2000).
  Medline CASGoogle Scholar
• 34  Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol.22(4 Suppl. 11),72–79 (1995).
  Medline CASGoogle Scholar
• 35  Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res.2,521–530 (1996).▪ Important study demonstrating the mechanisms underlying the synergistic interaction between gemcitabine and cisplatin.
  Medline CASGoogle Scholar
• 36  Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res.8,2286–2291 (2002).
  Medline CASGoogle Scholar
• 37  Park DJ, Zhang W, Stoehlmacher J et al.ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin. Adv. Hematol. Oncol.1,162–166 (2003).
  MedlineGoogle Scholar
• 38  Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer91,344–354 (2004).
  Medline CASGoogle Scholar
• 39  Viguier J, Boige V, Miquel C et al.ERCC1 codon 118 polymorphism is a predictive factor for the tumour response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res.11,6212–6217 (2005).
  Medline CASGoogle Scholar
• 40  Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol.15,1194–1203 (2004).
  Medline CASGoogle Scholar
• 41  Allan JM, Smith AG, Wheatley K et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood104,3872–3877 (2004).
  Medline CASGoogle Scholar
• 42  Gu J, Zhao H, Dinney CP et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin. Cancer Res.11,1408–1415 (2005).
  Medline CASGoogle Scholar
• 43  Chew HW, Doroshow JH, Frankel P et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J. Clin. Oncol.13,2163–2169 (2009).
  Google Scholar
• 44  Sissung TM, Danesi R, Price KM et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther.1,19–26 (2008).
  Google Scholar
• 45  Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis.17,46–49 (2002).
  MedlineGoogle Scholar
• 46  Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol.25,4528–4535 (2007).
  Medline CASGoogle Scholar
• 47  Stingl Kirchheiner JC, Brockmöller J. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. Clin. Pharmacol. Ther.89,198–209 (2011).
  Medline CASGoogle Scholar
• 48  Lunn RM, Helzlsouer KJ, Parshad R et al.XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis (Lond.)21,551–555 (2000).
  Medline CASGoogle Scholar
• 49  Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J. Natl Cancer Inst.92,440–441 (2000).
  Medline CASGoogle Scholar
• 50  McWilliams RR, Bamlet WR, Cunningham JM et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res.68,4928–4935 (2008).
  Medline CASGoogle Scholar
• 51  Duell EJ, Bracci PM, Moore JH, Burk RD, Kelsey KT, Holly EA. Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer. Cancer Epidemiol. Biomarkers Prev.17,1470–1479 (2008).
  Medline CASGoogle Scholar
• 52  Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res.14,1797–1803 (2008).
  Medline CASGoogle Scholar
• 53  Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer. RTOG 9704. Pharmacogenomics J. doi:10.1038/tpj.2011.22 (2011) (Epub ahead of print).
  MedlineGoogle Scholar